GleamWall
中文EN

VISK Viskase Holdings, Inc.

Biological Products, (No Diagnostic Substances) · OTC · SEC CIK 727510 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY59.0%
TTM EPS YoY182.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-21.6%
ROA-8.2%
ROIC (approx.)-4.0%
Asset turnover—

Leverage & solvency

Liabilities / assets58.4%
Debt / equity1.52x
Current ratio1.07x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.44x
Accruals ratio3.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$95.28M$90.13M$86.54M—$91.16M$97.28M$94.19M$0
Cost of revenue$86.78M$79.03M$77.54M—$85.30M$85.64M$79.78M—
Gross profit$8.50M$11.10M$9.00M—$5.87M$11.63M$14.41M—
R&D expense$736,000$649,000$558,000—$851,000$668,000$662,000—
SG&A expense$11.19M$12.15M$12.43M—$13.52M$12.93M$11.70M—
Operating income-$3.13M-$2.02M-$4.33M-$1.47M-$9.06M-$2.63M-$14.40M-$325,000
Pretax income-$6.41M-$4.83M-$5.97M-$1.04M-$11.05M-$5.91M-$15.01M$221,000
Income tax$28,000$305,000$748,000$26,000$1.95M$14.35M-$1.41M$293,000
Net income-$6.40M-$5.06M-$6.69M-$1.07M-$12.98M-$20.25M-$13.59M-$72,000
EBITDA$934,000$2.40M-$105,000—-$4.94M$2.28M-$9.02M—
EPS (basic)-0.45-0.35-0.84—-2.40-3.74-2.65—
EPS (diluted)-0.45-0.35-0.84—-2.40-3.74-2.65—
Dividends declared per share0.000.000.00—————
Weighted avg. shares (diluted)14.33M14.33M7.93M—5.42M5.42M5.13M—
Balance sheet
Cash & equivalents$7.75M$7.91M$28.62M$9.22M$7.69M$8.91M$5.75M$5.70M
Receivables$69.98M$67.39M$62.83M$60.18M————
Inventory$100.34M$105.30M$98.85M$96.75M————
Current assets$226.32M$227.34M$234.58M$208.65M$43.67M$44.74M$45.52M$47.15M
PP&E, net$155.59M$147.65M$142.95M$141.30M————
Goodwill$3.04M$3.05M$3.07M$3.13M————
Intangibles$12.20M$12.62M$12.89M$13.40M————
Total assets$427.47M$424.48M$428.87M$402.14M$43.69M$44.78M$45.52M$47.17M
Current liabilities$210.73M$123.63M$116.94M$214.52M$540,000$803,000$554,000$1.68M
Short-term debt$135.71M$54.47M$51.10M$141.77M————
Long-term debt$135.71M$74.93M$79.73M$141.77M————
Total debt$271.41M$129.40M$130.83M$283.55M————
Total liabilities$249.72M$238.87M$237.79M$257.78M-$100.62M-$115.04M-$128.13M-$122.82M
Shareholders' equity$178.94M$186.80M$192.20M$145.84M-$923,000$432,000$1.95M$3.01M
Net debt$263.67M$121.49M$102.22M$274.33M————
Shares outstanding14.33M14.33M14.33M6.61M74.21M74.21M74.21M74.21M
Cash flow statement
Operating cash flow$454,000-$11.21M-$16.32M-$682,000$10.12M$2.24M$129,000$226,000
Capital expenditure$6.59M$7.70M$8.98M—$9.25M$8.99M$7.35M—
Free cash flow-$6.14M-$18.90M-$25.30M—$870,000-$6.75M-$7.22M—
Investing cash flow-$6.59M-$7.70M-$8.98M—-$9.25M-$8.99M-$7.35M—
Financing cash flow$6.08M-$1.75M$44.75M$0-$2.06M$9.64M$7.19M$0
Depreciation & amortization$4.07M$4.42M$4.23M—$4.12M$4.91M$5.38M—
Dividends paid———$0$0$0$1.27M$0

Free plan shows the latest 8 periods; Pro shows all 66 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.